Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-08-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（章国标、周娟英、马卫民）
Regulatory Filings
2022-08-09 Chinese
独立董事候选人声明（章国标、周娟英、马卫民）
Regulatory Filings
2022-08-09 Chinese
安旭生物关于变更注册资本、修订《公司章程》并办理工商变更登记手续的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from a company regarding changes to its registered capital and amendments to its Articles of Association (company bylaws). It details the approval of capital increase through profit distribution and capital reserve conversion, and the corresponding amendments to the company's charter. It also mentions the authorization of the board to handle the registration changes with the industrial and commercial authorities. There is no financial statement or detailed financial report included, but rather a formal announcement of corporate governance and capital structure changes. This fits the category of Share Issue/Capital Change (SHA) as it involves changes in registered capital and related corporate documents.
2022-08-09 Chinese
安旭生物关于召开2022年第二次临时股东大会的通知
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed notice about convening the 2022 second extraordinary general meeting of shareholders for Hangzhou Anxu Biotechnology Co., Ltd. It includes information about the meeting date, voting methods, agenda items such as changes in registered capital, amendments to the articles of association, and election of board members and supervisors. It also contains instructions for shareholder registration, proxy voting, and cumulative voting procedures. The document is not a financial report, earnings release, or audit report, but rather a formal announcement and detailed information related to a shareholders' meeting. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it includes detailed voting agenda and instructions for voting rights. The document length and content confirm it is not a brief announcement but a full notice with voting details.
2022-08-09 Chinese
安旭生物关于董事会、监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the re-election of the company's board of directors and supervisory board. It details the nomination and election process, candidate qualifications, and meeting dates related to the board and supervisory committee. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and supervisory members, which fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a full announcement, not a brief notice or certification, so it is not RPA or RNS. Therefore, the correct classification is MANG with high confidence.
2022-08-09 Chinese
安旭生物公司章程（2022年8月）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Articles of Association" or "Company Bylaws". It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It references relevant laws and regulations, and includes sections on shareholder meetings, board of directors, management, financial accounting, profit distribution, and amendments to the articles. This is a governance document that sets out the internal rules and structure of the company rather than a financial report, announcement, or other filing type. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial and contains the full text of the articles, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear nature of the document as company bylaws.
2022-08-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.